Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilars At US FDA: Personnel Spending Losing Influence Over Program

Executive Summary

Percentage of personnel spending as a proportion of biosimilar review costs dropped more than 17% over three-year period as equipment and other spending more than doubled.


Related Content

Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says
US FDA Reorg: Centers Will Report Directly To Gottlieb; 'Flattened' Structure Will Make Future Political Transitions Easier
US FDA Biosimilar User Fee Collections, Expenditures Hit A High Point In 2017
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Biosimilar User Fee Reboot: Resource Challenges Make FDA Eye New Structure
Generic Drug Review Costs Still Largely Non-Personnel Related





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts